<DOC>
	<DOCNO>NCT02039323</DOCNO>
	<brief_summary>The purpose study determine feasibility novel method assess antiretroviral efficacy protection HIV-1 infection vaginal cervical tissue biopsy .</brief_summary>
	<brief_title>A Feasibility Study Assess Tenofovir Maraviroc Protection Against HIV-1 Cervical Vaginal Explants</brief_title>
	<detailed_description>Participants : Six premenopausal healthy volunteer woman 18-49 year age intact uterus cervix . Procedures ( method ) : Subjects give single dose two oral antiretrovirals ( maraviroc 600mg/tenofovir 600 mg ) . Subjects monitor assessed adverse event post-dose . Subjects send home ask return 24 hour . 24 hour post-dose , two vaginal two cervical biopsy obtain . These biopsy place ex-vivo culture system expose HIV . Viral RNA measure two day determine whether tissue protect infection . A final visit safety conduct 7-14 day post-enrollment .</detailed_description>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Healthy premenopausal female subject age 1849 , inclusive , intact uterus cervix . ( Healthy define irregular menstrual cycle clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12lead ECG clinical laboratory test ) All subject must estimate calculated creatinine clearance ( eCcr ) least 80 mL/min CockcroftGault formula : eCcr ( female ) mL/min = [ ( 140 age year ) x ( weight kg ) x 0.85 ] / ( 72x serum creatinine mg/dL ) . All subject must negative serum pregnancy test screen negative urine pregnancy test day dose administration use least one follow method contraception screen visit 72 hour prior first outpatient visit ( time woman ask remain abstinent followup visit ) Systemic hormonal contraceptive ( oral , depot , transdermal implant ) Intrauterine device place least 1 month prior study enrollment Bilateral tubal ligation ( Sterilization ) Vasectomized male partner Condom + Spermicide Unless engage sexual activity female sex partner abstinent least 3 month prior intention become sexually active study period . Any history recent present concomitant male sex partner address ruled context screen participant eligibility protocol Body Mass Index ( BMI ) approximately 18 34 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . Evidence personally sign date informed consent document indicate subject inform pertinent aspects trial . Willing able comply schedule visit , treatment plan , laboratory test , trial procedure . Subject must documentation normal pap smear within 36 month screen visit , procedures abnormal cervical/vaginal pathology last six month , least one prior gynecological visit part subject 's routine medical history . If subject gynecological exam history Pap smear , Pap smear complete screening pay study . Subject must willing abstain sexual intercourse , douche , intravaginal object product least 72 hour prior first study visit study completion . Subject must HIV1 Hepatitis B surface antigen negative document screen lab . Subject must actively involved conception process . Subject must able swallow pill allergies component study product . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include document drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Subjects history hysterectomy , clinically significant surgery female genital tract . Subjects pregnant , possibly pregnant lactate Subjects presence vaginal discharge genital bleed screen History febrile illness within five day prior medication dose . Any condition possibly affect drug absorption ( eg , gastrectomy ) . A positive urine drug screen . A positive result HIV . Active Hepatitis B infection determine positive Hepatitis B surface antigen ( HBsAg ) Hepatitis B core antibody ( HBcAb ) test ( absence HBsAb ) . Active Hepatitis C ( HCV ) infection define positive HCV Ab ( determine multiantigen EIA ) detectable Hepatitis C RNA . A positive test syphilis , gonorrhea , Chlamydia , trichomonas screening . Any laboratory chemistry hematology result Grade 2 great accord Division Allergy Infectious Disease ( DAIDS ) Laboratory Grading Tables Treatment investigational drug within 4 month precede first dose trial medication . History regular alcohol consumption exceed 14 drink ( 1 drink = 5 ounce ( 150 mL ) wine 12 ounce ( 360 mL ) beer 1.5 ounce ( 45 mL ) spirit ) per week . Use prescription nonprescription drug , vitamin , dietary supplement within 7 day 5 halflives ( whichever longer ) prior first dose trial medication unable avoid use inpatient pharmacokinetic visit . As exception , systemic hormonal method contraception continue . History sensitivity heparin heparininduced thrombocytopenia . Allergy lidocaine Monsel 's solution . Allergy latex . Abnormal pap smear past 12 month Any degree ectopy abnormality evident pelvic exam screen . Any condition , opinion investigator , likely interfere followup ability take study medication appropriately . Unwilling unable comply follow dietary concomitant drug restriction regard study drug administration outline study procedure prohibit medication section . Subjects allow eat drink grapefruit contain product 7 day prior first dose trial medication collection biopsy sample . Must refrain take prescription , nonprescription , herbal , vitamin dietary supplement within least 7 day study visit completion study without discuss study staff .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Tenofovir</keyword>
	<keyword>Tenofovir disoproxil</keyword>
	<keyword>Maraviroc</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Anti-HIV agent</keyword>
	<keyword>Pharmacodynamics</keyword>
</DOC>